“The initiation of this Phase 3 trial and the dosing of the first patient are significant achievements in the development of SPD8,” said Dr. Mei-Chun Yang, CEO of GlycoNex. “As the demand for ...
Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks ...
PARIS, France and Parsippany, NJ, USA I December 17, 2024 I Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today ...
Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in ...
CHICAGO, IL and FORT WORTH, TX, USA I 17, 2024 I Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with ...
CINCINNATI, OH, USA I 16, 2024 I LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company announced the submission of a ...
SINOVAC has initiated a phase I/II clinical trial on its bivalent vaccine in China since September 2023. The results from Phase I/II clinical trial demonstrated that the vaccine candidate has ...
NEW YORK, NY, USA I 17, 2024 I Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
LONDON, UK I December 16, 2024 I Accord Healthcare Limited (Accord) announces that the European Commission (EC) has granted marketing authorisation for ...
COPENHAGEN, Denmark I 16, 2024 I Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN® mpox vaccine ...
ZUG, Switzerland I 13, 2024 I Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback